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Abstract
Objectives Medical devices are potentially good candidates for coverage with evidence development (CED) schemes, as 
clinical data at market entry are often sparse and (cost-)effectiveness depends on real-world use. The objective of this research 
was to explore the diffusion of CED schemes for devices in Europe, and the factors that favour or hamper their utilization.
Methods We conducted structured interviews with 25 decision-makers from 22 European countries to explore the charac-
teristics of existing CED programmes for devices, and how decision makers perceived 13 pre-identified challenges associ-
ated with initiating and operating CED schemes for devices. We also collected data on individual schemes that were either 
initiated or still ongoing in the last 5 years.
Results We identified seven countries with CED programmes for devices and 78 ongoing schemes. The characteristics of 
CED programmes varied across countries, including eligibility criteria, roles and responsibilities of stakeholders, funding 
arrangements, and type of decisions being contemplated at the outset of each scheme. We observed a high variability in how 
decision makers perceived CED-related challenges possibly reflecting country-specific arrangements and different experi-
ences with CED. One general finding across all countries was that relatively little attention was paid to the evaluation of 
schemes, both during and at their completion.
Conclusions CED programmes for devices with different characteristics exist in Europe. Decision-makers’ perceptions differ 
on the challenges associated with these schemes. More exchange of knowledge and experience will help decision makers 
anticipate the likely challenges in CED schemes for devices, and to learn from good practices existing elsewhere.
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Adoption and reimbursement of medical devices
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Introduction
At the time of the publication of the ISPOR ‘Good Practices 
for Performance-Based Risk-Sharing Arrangements (PBR-
SAs) Task Force’ report [1], it was acknowledged that there 
were two types of arrangements to aid the market entry of 
new technologies; finance-based and performance-based 
agreements. Briefly, in finance-based arrangements, agree-
ments between payers and manufacturers are purely finan-
cial and may involve for example price–volume agreements, 
price discounts or budget caps. In PBRSAs one of the key 
elements is that the price, or reimbursement of a technol-
ogy is linked to its performance which is assessed through 
a purposeful, prospective data collection.. Indeed, some of 
the earliest examples of PBRSAs concern coverage with evi-
dence development (CED) schemes that were initiated by the 
Centres for Medicare & Medicaid Services in the US and 
the Ontario Ministry of Health in Canada for medical proce-
dures and devices [2, 3]. In CED schemes, data are collected 
with the objective of reducing uncertainty concerning the 
clinical or cost-effectiveness of a health technology and to 
assist in future decisions about its reimbursement, coverage, 
or recommendations for its use. Typically, these schemes are 
centrally coordinated and require substantial data collection.
Since the publication of the Task Force’s report, two 
trends can be observed. Firstly, there has been a growth in 
the popularity of finance-based agreements, or simple price 
reductions, as compared with performance-based schemes. 
In a recent review of managed entry agreements in Europe, 
Dabbous et al. [4] note that ‘despite the interests in CED 
schemes, European countries have moved towards finance-
based agreements due to the complexities and burdens 
associated with PBRSAs’. The lack of appetite for complex 
agreements among policy-makers was also noted by Karls-
berg Schaffer et al. [5], who concluded that ‘there is a mis-
match between the enthusiasm in the academic literature for 
developing new approaches and the scepticism of payers that 
they can work, or are necessary for the foreseeable future’. 
Secondly, there has been a growth in the application of 
financed-based and performance-based agreements to drugs 
rather than to other types of technologies, which could be 
a response to the growing number of transformational, but 
highly expensive new drugs entering the market [6]. Many 
recent reviews of PBRSAs discuss issues that apply to health 
technologies in general but draw almost exclusively on drugs 
for their examples [4, 7–9].
In principle, medical devices are good candidates for 
PBRSAs, particularly for CED schemes, since there are 
often considerable uncertainties concerning their (cost-)
effectiveness. This is mainly because the data requirements 
to obtain market access are often less stringent than those 
for drugs, and therefore devices are generally adopted 
in clinical practice with relatively little clinical or eco-
nomic evidence [10, 11].. In contrast to pharmaceuticals 
where the market authorization and supervision is cen-
trally managed by the European Medicine Agency (EMA) 
(Regulation (EC) No 726/2004), the conformity assess-
ment procedures for medical devices of risk class II or 
higher in Europe are decentralized and operated by public 
or private notified bodies (NBs) which are designated by 
the EU member states. Evidence requirements for market 
authorization are regulated by the medical device regula-
tion (MDR), which also defines when a clinical investiga-
tion of the new device is required or when conformity 
assessment can be based on the equivalence principle with 
a previously marketed device. However, notwithstanding 
the requirements for clinical investigations, a controlled 
clinical trial, which demonstrates the relative effective-
ness compared to alternative treatments, is generally not 
mandatory for MDs. Besides the differences in the regula-
tory approaches compared with pharmaceuticals, certain 
sources of uncertainty around a medical device are rela-
tively less easy to explore by means of pre-market studies. 
Many devices are part of complex interventions, consisting 
of multiple behavioural, technological, and organizational 
components, and therefore their actual (cost-)effectiveness 
profile usually depends on a series of context-specific fac-
tors that are difficult to assess before their adoption in 
the real-world. For example, device performance in regu-
lar clinical practice often depends not only on the device 
itself, but also on the skills of the user [12, 13]. In addi-
tion, while finance-based agreements are also possible, 
the cost of adopting a new device depends not only on 
its price, but also the cost of any new procedures or other 
organizational changes that might be required for its use. 
Therefore, a price reduction for the device itself may have 
less of an impact on overall costs. Moreover, finance-based 
agreements do not resolve potential issues about uncer-
tainty in the effectiveness of the device, which both payers 
and patients may feel is important.
The pace of innovation in medical devices is consider-
able, with many new products entering the market every 
year. For example, in 2017, the number of patents in the 
field of medical technologies filed with the European Patent 
Office (EPO) was more than double compared to the number 
concerning pharmaceuticals (13,000 versus 6300), and the 
total expenditure on medical technologies in Europe was 
roughly estimated as €115 billion [14]. Given the relevance 
of the market and the above-mentioned challenges with evi-
dence generation at market launch, any policy tool such as 
CED, which foresees a controlled introduction of a technol-
ogy while collecting further post-market evidence, is highly 
relevant in the context of medical devices. However, despite 
the possible advantages of CED schemes for aiding coverage 
decisions regarding new devices, little is known about the 
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extent to which these schemes are used in Europe and the 
detailed perceptions of decision-makers regarding their utili-
zation [15–17]. Therefore, the objective of this research was 
to contribute to filling this gap by exploring the character-
istics and diffusion of CED schemes for devices in Europe, 
and the challenges that decision-makers face during the dif-
ferent phases of a scheme [1, 14]. Our aim was to assist 
those considering the implementation of CED schemes for 
medical devices and to increase the understanding of both 
how schemes are currently being applied in Europe and how 
the challenges associated with them are being addressed.
Methods
This study is part of the EU Horizon 2020 COMED pro-
ject that has been reviewed and approved by the Bocconi 
University Ethics Committee (protocol number: 0068538, 
approved on May 8, 2018).
The research was conducted in three consecutive steps: 
(1) development of a structured interview guide (2) inter-
views with decision-makers from a sample of European 
countries, (3) synthesis and qualitative content analysis 
of the interview data, the data made available by the deci-
sion-makers during or following the interview, and data on 
scheme characteristics previously obtained [17]. The steps 
are described in more detail below.
Development of the interview guide
We developed a structured interview guide (Online 
Resource 1) that consisted of three sections. Section A 
included general questions on whether CED programmes 
underpinning the individual schemes existed in the deci-
sion-maker’s country and for which type of technology 
they were used. Section B included questions on 13 chal-
lenges for CED schemes for devices (Table 1). This list 
was derived from a recent systematic review that identi-
fied 20 challenges for CED schemes for devices [17]. To 
reduce the participants’ burden, we reduced the original 
list of 20 challenges to 13, by grouping different aspects 
of the same general challenge. The final list of challenges 
was discussed and agreed among all authors to ensure that 
all relevant aspects originally identified were covered in 
the interview guide (see the Online resource 2 for more 
details).
We asked the decision-makers to assess how they per-
ceived the 13 challenges to apply to CED schemes for 
devices on a six-point Likert scale (ranging from 0 “not a 
challenge” to 5 “a major challenge”). Where CED schemes 
for devices existed, we also asked respondents how the 
challenges were met in their country, and the interview pro-
ceeded to Section C. Otherwise, the interview ended here. 
Section C included questions on the detailed characteristics 
of individual CED schemes for devices that had been either 
initiated or still ongoing in the past five years. These ques-
tions concerned a description of the device under evalua-
tion, its clinical application, the objective of the scheme, key 
sources of uncertainty, funding of the scheme, its design, the 
decision rule, and outcome (if re-assessment was done), and 
any public source of information on the scheme.
Table 1  phases of CED schemes
Assessing the desirability of a scheme
This initial phase relates to the way candidate technologies for CED schemes are identified and selected. It also concerns the criteria used to 
assess whether a scheme is a good policy option, compared with other available options such as, for example, fully adopting the technology 
despite the residual uncertainties; refusing to adopt the technology until better evidence becomes available; or negotiating/mandating a lower 
price for the technology.
Designing the scheme
 This phase is about deciding on the specific features of the scheme design. These include, for example, the categories of patients who will 
have access to the technology during the scheme (e.g., Only in Research or Only With Research schemes), and the characteristics of the 
data collection plan, such as the study design (e.g., registry-based studies versus randomized controlled studies), the duration of the data 
collection, and the types of outcomes to be measured.
Implementing the scheme
 Reflecting the previous design phase, this phase is about the different ways schemes are operated and how roles and responsibilities are dis-
tributed among the stakeholders involved (e.g., the national/regional HTA agencies, the manufacturers, or the providers collecting the data). 
Relevant aspects are, for example, who will initially design the study protocol, who will coordinate and/or perform the data collection, 
monitoring and analysis, and who will fund the provision of care and the extra costs of collecting the new evidence.
Evaluating the scheme
 This phase relates to the types of decisions/policy updates that are made at the end of the scheme once the data collection is concluded and 
the new evidence has been assessed along with other evidence that has become available. It also concerns the way data collection is moni-
tored during the scheme and the definition of any stopping rule or intermediate assessment of the evidence being collected
 C. Federici et al.
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Interviews with decision‑makers
A first draft of the interview guide was circulated for com-
ments among the COMED project partners. Subsequently 
the final draft of the interview guide was pilot tested during 
interviews with one Italian policy maker and two academic 
experts with extensive experience of CED in Canada and the 
USA, two countries with a substantial number of schemes.
The interviews were conducted face-to-face or by tel-
ephone between June and December 2019. Decision-mak-
ers from decision bodies at the central (or in two cases 
regional) level were identified from the professional net-
works of the members of the  COMED project team or 
the websites of relevant decision bodies in the following 
European countries: Austria, Belgium, Bulgaria, Croa-
tia, Czech Republic, Denmark, England, Finland, France, 
Germany, Greece, Hungary, Iceland, Ireland, Italy, the 
Netherlands, Norway, Poland, Portugal, Romania, Scot-
land, Slovakia, Slovenia, Spain, Sweden, and Switzer-
land. Other countries from the EU/EEA were excluded 
because it was not possible to identify a relevant decision-
making body for the technology assessment of medical 
devices. We invited decision-makers to participate in the 
study by sending them an email with information on the 
COMED project and the objective of our study. When 
we were unable to identify a decision-maker from the 
networks or websites, we sent the information and invita-
tion to the relevant decision bodies. In three cases where 
no relevant decision-maker could be identified (i.e. Bul-
garia, Czech Republic, and Sweden), we invited academic 
researchers with relevant expertise to participate. None 
of these countries had however any CED programme for 
devices in place. We interviewed more than one decision 
maker from a given country in cases where schemes were 
operated in more than one jurisdiction (i.e., Italy), where 
more than one decision body was involved in operating 
schemes (i.e., France), or where more than one decision-
maker, from different parts of the relevant organization, 
agreed to participate (i.e., England). We excluded Croatia, 
Iceland, Romania, and Slovenia from our sample after 
repeated attempts to schedule an interview by December 
2019 were unsuccessful. Information on the individual 
CED schemes provided by decision-makers during or fol-
lowing the interview was supplemented with information 
on individual schemes previously obtained [17], compiled 
in tabular form, and sent to the participants for a validity 
check.
Data analysis
The transcripts were subjected to qualitative content analysis 
using deductive coding to meet the objective of this research. 
The results of each interview were reported in a table by one 
author (CF) and assessed by two authors (CF and VRD) who 
independently extracted the relevant information. Agree-
ment on the data to be reported was then reached through 
discussion and further analysis of the original transcripts. 
The data obtained from Sections A and C of the interview 
guide, together with the data obtained prior to and follow-
ing the interviews were used to identify and classify the 
characteristics of the existing CED programmes for devices 
according to the four phases of CED schemes: 1) assessing 
the desirability of the scheme; 2) designing the scheme; 3) 
implementing the scheme, and 4) evaluating it (1). These 
phases are described in more detail in Table 2. The informa-
tion collected was then synthesised in a narrative review.
The data obtained from Section B of the interview guide 
were used to obtain insight into the participants’ perceptions 
Table 2  Challenges with CED 
schemes for medical  devicesa
CED coverage with evidence development
a Derived from Reckers-Droog et al. 2020 17
Challenge
1 Deciding which medical devices are candidates for CED schemes
2 Obtaining stakeholder agreement on the scheme
3 Securing funding for the scheme
4 Determining the appropriate study design for data collection
5 Determining the relevant outcome measure(s) on which data are collected
6 Dealing with data collection and monitoring
7 Dealing with data analysis
8 Ex-ante definition of decision rule, based on possible outcomes of the scheme
9 Reaching an agreement on price, reimbursement or use of the device at the end of the scheme
10 Withdrawing a device from the market when evidence indicates the device is not (cost-) effective
11 Obtaining agreements about the duration of the scheme and the stopping rule
12 Adapting the scheme to account for product modifications or a learning curve
13 Dealing with the market entry of similar devices
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of the 13 challenges and into the factors that influenced 
their score for a particular challenge. The quantitative data 
obtained from Section B were used to calculate the mean 
(SD) and median (IQR) Likert scores for the 13 challenges 
(excluding the challenges that were marked as ‘not applica-
ble’ by the participants). Then, we calculated these statis-
tics separately for participants from countries with and from 
countries without a CED programme for medical devices. 
Because of the small sample sizes, we did not examine the 
differences in scores by performing statistical tests, but all 
factors which were perceived as having a positive or nega-
tive influence on each challenge were synthetized in tabular 
form.
Results
We interviewed 25 participants from 23 jurisdictions. 
Respondents were from national or regional health 
authorities (n = 15); national health insurance bodies 
(n = 2); hospitals (n = 3); and universities (n = 3) (see 
Online Resource 3 for details). Eighteen participants had 
high-level managerial roles related to the HTA of medi-
cal devices or services, or were responsible for the CED 
programme in their jurisdiction; four participants were 
technical advisers directly involved in the assessment of 
medical devices, and three were academics with an exper-
tise in conditional reimbursement schemes. In seven out 
of the 23 jurisdictions (30.4%), CED programmes existed 
that included (or were specific to) schemes for medical 
devices (i.e., Belgium, England, France, Germany, the 
Netherlands, Spain, and Switzerland). In France, two dif-
ferent programmes were identified: Post Registration Stud-
ies (PRS) for devices submitting for registration into the 
positive list of reimbursable products and services (LPPR 
list); and Forfait innovation (FI) for highly innovative tech-
nologies early in their development phase. Of the remain-
ing jurisdictions, 5 (21.7%) operated CED programmes for 
drugs only (i.e., Bulgaria, Hungary, Portugal, Scotland, 
and Slovakia), and 11 (47.8%) did not operate any CED 
programmes (i.e., Austria, Czech Republic, Denmark, Fin-
land, Greece, Ireland, Italy-Emilia Romagna Region, Italy-
national level, Norway, Poland and Sweden), although 
some of these may have other types of PBRSAs such as 
performance linked reimbursement schemes (e.g., payment 
by results schemes). In addition, single ‘one-off’ expe-
riences with schemes for specific devices were reported 
by participants from Emilia Romagna Region in Italy and 
Ireland, in the absence of formal programmes for CED 
schemes for devices.
Overall, we identified 78 CED schemes for devices 
which were ongoing in the last 5  years in Europe. A 
full overview of the characteristics of these schemes is 
included in Online Resource 4. Table 3 and Fig. 1 pre-
sent an overview of how the existing national CED pro-
grammes underpinning the individual schemes address the 
different phases of CED schemes. Our main findings are 
highlighted below.
Assessing the desirability of a CED scheme
We identified three main ways in which devices are 
selected for a scheme (Table  3). Firstly, a device can 
be selected as the direct result of a formal health tech-
nology assessment (HTA), if the decision body making 
the assessment identifies remaining uncertainties on the 
device (cost-)effectiveness and therefore propose initia-
tion of a scheme. Such HTAs can be conducted for exam-
ple, in the context of i) a request from a manufacturer to 
include the device on a positive reimbursement list (e.g., 
Belgium, France—PRS, the Netherlands and Switzerland); 
ii) a request from a provider for an extra remuneration of 
the procedure involving the device, for example on top of 
an existing diagnosis-related group -DRG tariff (e.g., in 
Germany); or iii) a request for an evaluation of a proce-
dure or device already in use in clinical practice (e.g., in 
Belgium, Germany, Spain and Switzerland). Secondly, a 
device could be selected following an active screening of 
potential candidates for CED schemes conducted by the 
decision body or by a committee specifically appointed 
for this task (e.g., in England or Spain). Finally, a device 
could be selected following a direct application to initiate 
a CED scheme by manufacturers or other stakeholders, 
such as care providers and health insurers with an interest 
in the device (e.g., in Belgium, France—FI studies, the 
Netherlands and Switzerland).
In all jurisdictions criteria are used to select and/or pri-
oritize devices for inclusion in a scheme, and decisions 
are made either through a deliberative process or using 
an explicit scoring system or checklist. However, a formal 
assessment of the pros and cons of initiating a scheme, as 
opposed to other policy decisions, such as providing uncon-
ditional coverage, or refusing to adopt the device until better 
evidence becomes available, was never clearly defined.
Designing a CED scheme
We identified differences in the design of schemes between 
countries. For example, Spain and Switzerland mainly 
operated schemes in which a device is reimbursed for all 
indicated patients while data are collected in a subset of 
patients (i.e., only with research—OWR), whereas England, 
the Netherlands and Belgium mainly operated schemes in 







Table 3  Overview of the characteristics of CED programmes for medical devices in Europe
England France Germany Netherlands Spain Switzerland Belgium
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als are submitted 
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technology’s short or 
long-term outcomes, 
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lection of new data 
through a PRS
During the evaluation procedure 
of a diagnostic and therapeutic 
method, if the opinion of the 
IQWIG reports that the benefit 
has not been confirmed, but 
the method offers the potential 
of being a treatment alterna-
tive. Requests for the evalu-
ation of methods may be put 
forward by 1) stakeholders 
organizations for inpatient (§ 
137c, SGB V) and outpa-
tient (§ 135 SGB V) care, 2) 
directly by manufacturers (§ 
137e SGB V) or 3) by hospi-
tals, submitting a first request 
for NUB payment to the InEK 
(§ 137 h SGB V)
Technologies can be 
identified in 2 ways: 1) a 
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negative view following 
an assessment, whether 
an intervention can be 
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Table 3  (continued)
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the French social 
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Table 3  (continued)
England France Germany Netherlands Spain Switzerland Belgium
 Type of CED 
 schemeb
Only in research FI: Only in research, 
PRS: Only with 
research
Only with research for Inpatient 
care, Only in research for 
outpatient care
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ment Centre for 
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and data analysis
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for the procedure and 
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appraisal, the device 
is temporarily listed 
in LPPR and covered 
by the social health 
insurance. Costs of 
data collection and 
analysis fall on the 
manufacturers
G-BA coordinates all phases of 
the design and implementation 
of the scheme. The diagnostic 
and therapeutic method under 
evaluation is covered by the 
health insurance. Overheads 
of the study can be financed 
by the manufacturer of the 
device being evaluated or are 
financed by statutory health 
insurance via G-BA
The care provided is 
covered by the basic 
insurance package. The 
reimbursement rate is 
negotiated between the 
health insurance compa-
nies and the participating 
hospitals and included 
in a covenant agreement 
signed by all parties 
involved in the scheme. 
The costs of data col-
lection and analysis are 
covered by the scheme 
applicants. However, 
there is the possibility to 
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by the regions 
participating 
in the scheme. 
Participating 
hospitals do not 
receive extra 
funding for data 
collection
The reimburse-
ment of the 
procedure is 
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ance. Costs of 
data collection 
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Table 3  (continued)
England France Germany Netherlands Spain Switzerland Belgium
 Definition of 
study protocol
The study protocol 
is developed 
by the External 
Assessment Cen-
tre in partnership 
with NICE
FI: The study protocol 
is directly submitted 
by the scheme appli-
cant and evaluated 
by the HAS
PRS: The responsibil-
ity of defining the 




tions on the type of 
uncertainties that 
must be addressed 
by the scheme, and 
approve the final 
version of the study 
protocol
The key aspects of the study 
are defined in the directive 
approving the scheme. The 
protocol is then refined by 
the research institution that 
conducts the study
Development of the 
study protocol is a 
direct responsibility of 
the scheme applicant. 
ZIN assesses the study 
proposal in collabora-
tion with the Scientific 
Advisory Council (WAR) 
and ZonMw
The study protocol 
is defined by the 
regional HTA 
agencies partici-
pating in the data 
collection
The design of the 
protocol is a 
responsibility 
of the scheme 
applicant. The 
proposal is then 
evaluated and 
approved by the 
FOPH
The relevant 
questions to be 
answered in the 
scheme and the 
set-up of the reg-
istry are proposed 
by the CTIIMH 
and discussed with 
the stakeholders 
involved, to obtain 
an agreement. 
Outcomes to be 
considered are dis-
cussed between the 
expert scientific 
community and 
the CTIIMH which 
also approves the 
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tion is overseen 
by the appointed 
steering group, 
and supported 




low ups are done 
on the quality 
and validity of 
data submitted to 
ensure mean-
ingful data is 
being collected. 
Analysis of the 
data is done 
by the external 
assessment centre 
and reviewed by 
NICE
FI and PRS: The 
responsibility for 
both the data collec-
tion and analysis falls 
on the manufacturer 
only. For PRS stud-
ies, the CNeDMTs 
evaluate the quality 
of the new evidence 
provided at the 
time of the planned 
re-appraisal of the 
technology
Data collection and analysis are 
done by an external research 
institution which has been 
appointed by G-BA through a 
public tender, if the overheads 
are financed via G-BA
The scheme applicant has 
the main responsibility 
for data collection and 
monitoring. The ZIN 
monitors the course of 
the scheme and reports it 
annually to the Minister 
of Health. ZIN assesses 
the new evidence pro-
vided at the time of the 
planned assessment of 
the technology
Data collection 











lance, and yearly 
reporting to the 
CPAF on the 










have to be 
reported to the 
FOPH, showing 




changes to the 
scheme or even 
cause early 
termination, if 
issues arise with 
data collection 
(e.g., poor qual-
ity of the data, 
slow recruit-
ment)
Data collection is 
a responsibility 
of the hospitals 
that have signed 
the agreement to 
participate in the 
scheme. Depend-
ing on the agree-
ment, the hospitals 
or an external peer-
review group/sci-
entific association 





rules for the 
scheme linking 
the results of 
the scheme 
to a deci-
sion on price, 
reimbursement 
or use
No No (both FI and PRS) No Agreements regarding the 
uptake of the interven-
tion, in case of a positive 
coverage decision at the 
end of the scheme, or 
exit strategies in case of 
a negative opinion (e.g., 
because the intervention 
is not effective, or the 
data quality is considered 
insufficient to take a 
decision) are defined in 
the convenant agreement 
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Results of the 
scheme are used 
for the develop-
ment of Clinical 
Commission-







provided only for 
the duration of the 
scheme, then devices 
enter usual evalua-
tion pathways (e.g., 
a new request by the 
manufacturer for 
inscription in the 
LPPR)
PRS: confirma-
tion of the device 
in the LPPR and 
refinements of the 
conditions of use. 
Financial penal-
ties on the price of 
the device may be 
applied in case of 
poor data quality at 
reassessment
Confirmation of the reimburse-
ment status




status under the 
same conditions 
of use, changes 
to the condi-
tions of use or 
withdrawal of 
the technology 







use, and changes 
in the maximum 
reimbursement 
rate for the 
technology or 
procedure
Confirmation of the 
reimbursement 
status
a Starting from 2019, conditional admission schemes have started to be gradually replaced by schemes within the new Promising Care Subsidy Fund (PCSF). The main difference between the two pro-
grammes concerns the way care provision is reimbursed during a scheme, i.e., directly subsidized in the PCSF rather than covered by the statutory health insurance as in conditional admission schemes. The 
schemes already ongoing will be completed according to the VT programme described in the Table
b “ Only in research” are defined as schemes in which a device or procedure is reimbursed only for patients who enrol in a clinical study, whereas “Only with research” schemes are defined as schemes in 
which a device or procedure is reimbursed for all indicated patients while data are collected in a subset of patients
c Conditionally approved care is only covered if the patient participates in the main study. However, patients who are not able to participate can claim the conditionally approved care if they participate in 
a supplementary ancillary study. CNEDiMTS, French Medical Device and Health Technology Evaluation Committee; CRGs, Clinical Reference Groups (England); CTIIMH, Belgium Implant and Inva-
sive Medical Device Reimbursement Committee;; FOPH, Swiss Federal Office of Public Health; G-BA, German Federal Joint Committee; InEK, German Institute for the Hospital Remuneration System; 
IQWiG, German Institute for the Hospital Remuneration System; LPPR, List of Products and Services qualifying for Reimbursement (France); RCTs, Randomized Controlled Trials; RIZIV, Belgian Medi-
cines Verification Organisation; ZIN, Netherlands National Health Care Institute; ZonMW, Netherlands organisation for Health Research and Development, Implant and Invasive Medical Device Reim-
bursement Committee
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in a clinical study (i.e., only in research—OIR). In France 
schemes were either OIR in the FI programme or OWR in 
the PRS, whereas in Germany the type of schemes depended 
on whether the technology was intended for inpatient use 
(OWR) or outpatient use (OIR).
It is worth noting, however, that within countries, the 
designs were relatively similar between schemes and 
appeared not to be tailored to (the specific characteristics of) 
the device under evaluation or to key sources of uncertainty. 
Moreover, the study designs were similar between schemes 
Fig. 1  Overview of the main characteristics of CED programmes in Europe
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in each country and mainly concerned either observational 
designs utilizing real-world data, or experimental designs to 
ensure a high level of evidence (e.g., randomized controlled 
trials).
Implementing a CED scheme
We observed differences in the governance of CED schemes 
as well as in the roles and responsibilities of the stakeholders 
involved, regarding the development of the research protocol 
and the subsequent monitoring of the scheme. Overall, we 
identified two main approaches. In the first approach (e.g., in 
France, the Netherlands and Switzerland), the responsibility 
for the development of the study protocol, the monitoring 
of the scheme and the quality of the generated data relies 
entirely on the scheme applicants (e.g., the manufacturer 
or care providers). However, in defining the study protocol 
the applicants typically must follow the recommendations 
of the relevant decision body. Usually, the protocol requires 
formal approval before study initiation, to make sure that it 
is suitable for addressing the identified uncertainties regard-
ing the device. In the second approach, the responsibility 
for the development of the study protocol and the quality of 
the generated data are coordinated centrally (e.g., by HTA 
agencies), and managed either directly or through third-party 
research centres (e.g., in Belgium, England, Germany and 
Spain).
Patient representatives may be involved in the initial 
assessment phase on the desirability of the scheme (e.g., in 
Spain or France) or later during the recruitment phase of the 
study (e.g., in England), but their involvement in the design 
phase and the development of the protocol was generally 
limited.
During the scheme, the costs of care provision (includ-
ing utilization of the device) are usually funded through the 
public health care system. Specific funding arrangements 
may be defined at the onset to cover the additional costs 
of the device or procedure, by either establishing a forfeit 
or negotiating an add-on to an already existing DRG tariff. 
However, different arrangements exist for covering the addi-
tional costs associated with the research, including the costs 
of developing the study protocol, scientific monitoring, data 
collection and analysis. These costs may be either entirely 
financed with public funds (e.g., in Belgium, England and 
Spain) or they may be partially or entirely covered by the 
scheme applicant (e.g., in France, Germany, the Netherlands 
and Switzerland). Notably, in some cases, funding arrange-
ments also include resources for data collection. In other 
cases, health care providers are required to perform this task 
without any additional funding, for example, as a condition 
of participating in the scheme and gaining market access for 
the device (e.g., in Spain or Belgium).
Evaluating a CED scheme
Decisions at the end of schemes mainly concerned the con-
firmation of the reimbursement status of the device, the 
refinement of clinical indications or conditions of use. For 
most of the identified schemes, no ex-ante decision rules that 
explicitly linked the scheme results to future decisions were 
defined. In most countries the schemes solely concerned the 
collection of additional evidence to reduce the identified 
uncertainties, while the final decision on the reimbursement, 
coverage or use of the device was integrated in the routine 
decision-making framework. A notable exception was the 
Netherlands, where the level of effectiveness that must be 
demonstrated during the scheme to obtain unconditional 
reimbursement was predefined at the onset of the scheme, in 
a covenant agreement signed by all stakeholders. Moreover, 
the covenant also addressed how to manage the withdrawal 
of a device in case it proved to be insufficiently effective or 
the data did not allow an informed decision (e.g., due to poor 
data quality or inconclusive results).
Notably, all participants reported having no, or only very 
little experience, with schemes that led to a negative cov-
erage decision. Indeed, of the 24 CED schemes for which 
information on final decisions were available, coverage was 
confirmed (or conditional coverage prolonged due to data 
quality issues) in 22 cases.
Challenges associated with CED schemes for medical 
devices
Of the 25 participants, 18 scored the 13 challenges on the 
six-point Likert scales. Of these, nine were from jurisdic-
tions with CED programmes involving devices, and nine 
were from jurisdictions with CED programmes involving 
drugs only. The seven participants who did not score the 
challenges were from countries without CED programmes.
For most of the assessed challenges, scores were observed 
across the full range of the Likert scales, indicating no clear 
patterns in the decision-makers’ perceptions. Table 4 pre-
sents the mean and median scores for each challenge. Over-
all respondents from jurisdictions with CED programme 
for medical devices tended to give lower scores to most of 
the challenges as opposed to respondents from jurisdictions 
without such programmes. However, the low sample size 
and the variability in responses within each challenge ham-
pered any firm conclusion.
Table 5 presents the main factors that, according to the 
participants, positively or negatively influenced the chal-
lenges. Many of the factors identified are common to all 
technologies and consistent with the existing literature on 
CED schemes. However, some elements specific to devices 
could be identified.
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Devices were generally considered to be more difficult 
to identify and monitor than pharmaceuticals, given that 
their routes to market are often less clear and may not be 
observed by those who are responsible for selecting potential 
candidates for CED schemes. The intrinsic characteristics 
of devices were also reported to pose additional challenges 
in the design and implementation of schemes. For exam-
ple, device-user interactions and the context-specific factors 
which may affect device performance in the real-world were 
considered as challenges for the identification of all relevant 
uncertainty at the time of scheme initiation, and for the defi-
nition of the study protocol. In addition, devices may be 
associated with uncertainties that cannot be easily resolved 
within a feasible time frame for a scheme, such as uncer-
tainties over the devices’ durability or their long-term per-
formance in patients with different clinical conditions and 
physiologies. This in turn may increase the tension between 
the need to pragmatically rely on surrogate endpoints, which 
are rarely validated for MD procedures, and the relevance 
of the data collected to inform decision-making at the end 
of the scheme. In addition, routinely collected data, such 
as administrative datasets or electronic health records were 
expected to be less often available, or relevant, for devices, 
as compared with pharmaceuticals.
Relating to the possibility of product modifications dur-
ing the timeframe of the scheme, one of the main concerns 
related to the fact that such modifications could bias the 
results of the study or compromise the relevance of the new 
evidence collected. In this respect, being able to anticipate 
product modifications by means of dialogues with manufac-
turers and sharing of information was considered a poten-
tially mitigating factor. However, the possibility of product 
modifications was not perceived by most of the respondents 
as a major challenge, or something which is likely to occur 
during the duration of a scheme.
Similarly, about half of the respondents did not consider 
the possibility that similar products would enter the market 
during the period of the scheme to be an important chal-
lenge. Possible reasons related to the fact that most of the 
schemes evaluate a class of devices or a procedure rather 
than a single branded device, or that, even if focussed on 
a single product, they collected mainly non-comparative 
data. However, other respondents emphasised the difficulty 
of anticipating which products would enter the market dur-
ing the schemes and the possibility that relative effectiveness 
estimates may not be meaningful anymore by the end of 
the scheme, as clinical practice changes more rapidly in the 
context of devices compared to pharmaceuticals.
Table 4  Assessment of challenges by  participantsa
a Assessed on a six-point Likert scale (ranging from 0 “not a challenge” to 5 “a major challenge”)
b Two participants scored the challenges for this country
Challenge Participants from countries 
with CED programmes for 
medical devices (Belgium, 
 Englandb,  Franceb, Germany, 
Netherlands, Spain, Switzer-
land)
Participants from countries 
without CED programmes for 
medical devices (Bulgaria, 
Hungary, Ireland,  Italyb, 
Poland, Portugal, Scotland, 
Slovakia)
n Mean (SD) Median (IQR) n Mean (SD) Median (IQR)
1 Deciding which medical devices are candidates for CED schemes 9 2.5 (1.17) 2 (2.25) 9 3.78 (1.48) 4 (2.5)
2 Obtaining stakeholder agreement on the scheme 9 2.17 (1.46) 2 (2.75) 8 2.75 (1.83) 2.5 (3.5)
3 Securing funding for the scheme 9 0.89 (1.05) 1 (1.50) 8 3 (1.69) 3 (3.5)
4 Determining the appropriate study design for data collection 9 2.39 (1.45) 2 (2.75) 9 3.33 (1.32) 4 (2)
5 Determining the relevant outcome measure(s) on which data are collected 9 2.61 (1.27) 2 (2.50) 9 2.78 (1.72) 2 (3.5)
6 Dealing with data collection and monitoring 8 2.13 (1.64) 2.5 (3.5) 9 3.78 (1.2) 4 (2.5)
7 Dealing with data analysis 9 1.61 (1.22) 1.5 (2.5) 8 3 (1.51) 3.5 (2.75)
8 Ex-ante definition of decision rule, based on possible outcomes of the 
scheme
3 3 (1) 3 (2) 8 3.75 (1.58) 4.5 (2.75)
9 Reaching an agreement on price, reimbursement or use of the device at 
the end of the scheme
5 2.1 (2.13) 2 (4.25) 7 3.57 (1.27) 4 (3)
10 Withdrawing a device from the market when evidence indicates the 
device is not (cost-) effective
6 3 (0.89) 3 (2) 8 4.5 (1.07) 5 (0.75)
11 Obtaining agreements about the duration of the scheme and the stopping 
rule
9 1.94 (1.13) 2 (1.25) 8 1.75 (1.49) 1.5 (2.75)
12 Adapting the scheme to account for product modifications or a learning 
curve
8 1.44 (1.45) 1.5 (2.38) 8 3.25 (1.49) 3.5 (2.75)



























Table 5  Factors with positive and negative influence on challenges with CED schemes for devices
Challenge Factors with positive influence Factors with negative influence
1 Deciding which medical devices are candidates for CED 
schemes
There is a structured process leading to the identification of 
potential candidates for CED schemes
Prioritization and inclusion of technologies into a scheme is 
made according to explicit and shared criteria
The suitability of the proposed study protocol is a pre-condi-
tion to inclusion of a technology in a scheme
The request to provide additional data is applied to all tech-
nologies for which relevant evidence gaps are identified 
during an assessment and the main responsibility of data 
collection falls on the manufacturers/applicants
HTA processes for devices are less formalized, commission-
ing mainly occurs at the local level
A high number of devices and lack of horizon scanning 
processes to inform candidates for CED schemes of medical 
devices
Optimal allocation of the funds for CED schemes is hampered 
by the fact that proposals are evaluated at different times 
over the year
It is not easy to establish whether the available evidence is 
sufficient to initiate CED scheme or whether it is too early 
for reimbursement
2 Obtaining stakeholder agreement on the scheme There exists a well-defined and structured processes for 
stakeholder engagement
All details of the scheme, including the roles and obligations 
of the stakeholders involved are defined in a contractual 
agreement before scheme initiation
Relationships with clinicians and manufacturers are facili-
tated if CED schemes are perceived as the only means to 
use the technology
The responsibility to collect the data (and coordinate with 
participating centres and other stakeholders) fall on manu-
facturers/applicants
The complexity of CED schemes and the different expecta-
tions of the stakeholders involved require a strong and time-
consuming coordinating effort
For devices, it is more difficult to find patients to participate 
in public consultations during the scheme (e.g., compared to 
pharmaceuticals)
In countries with small markets manufacturers may have a 
high bargaining power when discussing the conditions for 
the schemes
3 Securing funding for the scheme Fixed budgets for CED schemes are granted on a periodic 
basis
The additional costs of running a scheme fall upon the 
manufacturers/applicants
Lack of ad hoc funds and/or human resources to run the 
schemes
4 Determining the appropriate study design for data collection The health authority can explicitly or implicitly mandate the 
type of study to be conducted
Study design is defined by a third-party research institution
CED schemes are mostly relying on routinely collected data
A registry on the disease/device is already in place and suit-
able to answer the research questions
Setting up the research governance is usually complex, with 
several organizations involved and many practical questions 
to answer
There may be disagreement on study design between the 
government, the manufacturers and the providers
Selecting the centres that will collect data for the schemes 
may be problematic and time consuming
Original patients’ informed consent for registries may not 







Table 5  (continued)
Challenge Factors with positive influence Factors with negative influence
5 Determining the relevant outcome measure(s) on which data 
are collected
The health authority defines the primary and secondary 
outcomes. Those responsible for carrying out the research 
must justify if they do not follow the indication
Clinicians and experts are involved from the onset in the 
definition of the outcomes
Previous evidence from the literature or international col-
laborations (e.g., EunetHTA reports) already outlined the 
most relevant outcomes
Relevant safety and effectiveness issues are more difficult to 
identify for devices compared to drugs at the time of the 
evaluation
Patient Reported Outcomes data are generally difficult to 
collect
A balance is required between what outcomes would be 
desirable and what can be pragmatically collected by the 
participating centres
Different stakeholders may disagree on the relative impor-
tance of the outcomes to be collected (e.g. surrogate versus 
patient relevant outcomes)
6 Dealing with data collection and monitoring Data collection is based on routinely collected data from 
electronic sources (e.g., electronic health records)
Feasibility of the data collection burden is discussed and 
agreed among all actors involved at the beginning of the 
scheme
There is interoperability of data across data sources and 
research centres/providers
Continuous follow-up is done to check the quality and 
validity of data submitted and to ensure meaningful data is 
being collected
There is less availability of routinely collected outcomes data 
for devices compared to pharmaceuticals
Uncertainties on devices may require the collection of long-
term outcome data, incompatible with the length of the 
scheme
Having to deal with many low-volume centres with different 
experience may affect data quality, and increase the collec-
tion effort
Hospitals/participating centres may lack incentives to provide 
timely and high quality data if they do not receive specific 
funding for this task
Recruitment may be slower than expected affecting the time 
when the scheme reports its results
7 Dealing with data analysis An independent research body is appointed for data analysis, 
including quality and risk of bias assessment
There is an established experience with data analysis
Difficult to find adequate controls with observational studies
Getting the analysis done and timely delivered may be difficult 
if no additional funds are provided for this task
8 Ex-ante definition of decision rule, based on possible out-
comes of the scheme
Schemes are only about collection of new data
Decision rules, including stopping rules during the schemes, 
and management of specific cases at the end of the data 
collection (e.g., insufficient quality of data, technology not 
effective) are defined in a contract agreed among all parties 
involved
Fixed decision rules at the onset may be affected by unfore-
seen changes in the devices or market dynamics
9 Reaching an agreement on price, reimbursement or use of 
the device at the end of the scheme
At the end of the scheme, technologies are re-evaluated 
according to business as usual evaluation procedures
The scheme may not have collected the planned data by the 
time of the reassessment, or data may be un-conclusory
Relevant differences in (cost) effectiveness less clear among 
similar devices compared to pharmaceuticals
10 Withdrawing a device from the market when evidence indi-
cates the device is not (cost-) effective
An exit strategy in case the technology is not (cost) effective 
is defined at the onset in a contract agreed between all 
stakeholders involved
Having a well-designed scheme which produces scientifi-
cally robust results
Patients and manufacturers may challenge the withdrawal 
decision and take actions against it
The management of explants for implantable devices in case 



























Table 5  (continued)
Challenge Factors with positive influence Factors with negative influence
11 Obtaining agreements about the duration of the scheme and 
the stopping rule
The duration of the scheme is agreed based on the time that 
is needed to collect the required data and the characteris-
tics of the disease/technology
Continuation of the scheme is linked to periodic monitoring 
on its progresses
Adopting the stopping rules defined at the onset of the scheme 
may be difficult when the scheme is ongoing
There is a tension between the short life-cycle of devices and 
the need for long-term outcomes
Different perspectives among involved stakeholders (e.g. clini-
cians, manufacturers, NHS and HTA bodies)
Slow recruiting may impact on the time when the study 
reports its results
12 Adapting the scheme to account for product modifications or 
a learning curve
The time frame of the scheme is relatively short to avoid 
product modifications
Considerations on the eligibility of a device to a scheme 
also consider if newer generations of the same devices are 
expected in the short-term
The company shares in advance available information on 
potential evolutions of the device and these are considered 
when discussing the study protocol
Data on the effect of the learning curve is publicly available
There is little policy experience with how to deal with product 
modifications and/or learning curves
Interpretation of results are confounded by product modifica-
tions that occur during the time-frame of the study
Existence of a learning curve may complicate the selection 
process of participating centres in the scheme
13 Dealing with the market entry of similar devices Schemes evaluate the class of devices or the procedure, not 
individual devices
A scheme can involve multiple devices from different manu-
facturers
Schemes are not comparative in nature. Any similar product 
entering the market may be requested to provide additional 
data or not based on their level of evidence
Manufacturers of similar devices entering the market after 
scheme is initiated may be required to provide data to the 
same nationally-wide registry
Identifying similar devices entering the market is hampered 
by the difficulty to do horizon scanning for devices
More rapid changes in clinical practice with devices compared 
to pharmaceuticals
Inclusion of a new device entering the market when the 
scheme is ongoing may be more difficult than including it 
from the beginning
CED coverage with evidence developmen
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Finally, with respect to the existence of a learning curve, 
interviewees acknowledged it as a challenge which affects 
both the collection and analysis of data, as well as the design 
of the study, such as deciding on the number of clinical cen-
tres authorized to use the device as part of the scheme. How-
ever, direct experience with this aspect was generally limited 
across all respondents.
Discussion
CED schemes and their application to medical devices are 
important items on the policy and research agendas. The 
objectives of this research were to explore the characteris-
tics and use of CED schemes for devices in Europe, as well 
as the challenges that decision-makers face when designing 
and operating these schemes. Our study importantly adds to 
the existing knowledge base by providing a comprehensive 
and multi-country overview, which was directly informed by 
surveys with European decision/makers.
We found that 78 device-related CED schemes have been 
operated over the last 5 years in European countries. How-
ever, only seven countries had CED programmes in place 
for medical devices. To a large extent, this result may reflect 
the uneven application of HTA within Europe, since it may 
be difficult to develop a policy for CED schemes without 
having an established HTA capacity. For example, deciding 
that more data are required post-launch implies that some 
form of assessment of clinical or cost-effectiveness has been 
made. Nevertheless, HTA capacity cannot fully explain these 
differences, since CED schemes seem to be less frequently 
used for devices than for drugs [15].
The characteristics of the identified CED programmes 
underpinning the individual schemes for devices varied 
between countries, which may reflect local differences in 
how HTA is organised and practised. For example, schemes 
were either initiated by the authorities (i.e., Ministry of 
Health), often as a consequence of the findings of an HTA 
for the technology, or as a response to a request from a man-
ufacturer. We found similar patterns in the relative respon-
sibilities for the funding of schemes and the design of study 
protocols although the authorities always played some role 
in study design, either by outlining a general specification 
or recommending that an independent research centre be 
involved. These differences in roles were also found in the 
aspects of the implementation of schemes, including the 
collection and analysis of data, which was sometimes the 
responsibility of the manufacturer and sometimes an inde-
pendent party.
One aspect that deserves attention is how devices are 
selected for a scheme. Indeed, CED is not a costless activ-
ity and its (opportunity) costs and benefits should be con-
sidered alongside other policy options, such as adopting 
or refusing adoption of the technology, based on currently 
available data, or negotiating a lower price. Aspects to 
be considered should include: 1) the expected value of 
research option(s) in terms of reduced uncertainty; 2) the 
direct costs of collecting evidence; 3) the opportunity costs 
of any delay in providing access to the technology because 
of the scheme; and 4) the existence of any irreversibility 
in the process (e.g. difficulty to subsequently withdrawal 
the technology, or difficulty to conduct further research 
after conditional approval) [1, 13]. However, while all the 
identified programmes used criteria to identify and pri-
oritize technologies for a scheme, a formal assessment of 
these aspects was generally missing. Related to the previ-
ous point. In many jurisdictions, there does not seem to 
be an option for choosing among different types of CED 
schemes, such as OWR and OIR schemes. Nonetheless, 
also depending on characteristics that are specific to, or 
particularly relevant for devices (e.g., the existence of 
irreversible upfront investment costs), there may be cases 
where either one or the other type of CED scheme would 
be optimal [13, 18]. As reported in the recent report from 
the ISPOR good practice Task Force, Value of Information 
(VOI) analysis may be used to support formal assessments 
on the opportunity to initiate a CED scheme and the type 
of scheme which maximizes optimal allocation of health-
care and research funds [19].
In addition, one general finding across all countries was 
that relatively little attention seemed to be paid to the evalu-
ation of schemes, both in itinere during data collection 
and at the time of the reassessment of the technology once 
the scheme reported its results. This mirrors the findings 
of other studies of CED and market access schemes more 
generally [1, 20, 21] and is obviously an area that requires 
further attention by policy makers and researchers. Indeed, 
issues with the quality and timely reporting of data have 
been mentioned as a factor hampering CED schemes (see 
e.g., Table 5). For example, in France, where manufacturers 
are solely responsible for the collection of additional data, 
the lack of the requested evidence from post-registration 
studies was often reported in the technology re-appraisals.
The policy responses at the end of a CED scheme for 
devices may be more complicated than, for example, decid-
ing on whether to include a drug on a formulary or to deter-
mine prescribing guidelines, since the reimbursement of 
devices, and the policies to determine their use, are often 
linked to the use of broader surgical, or other treatment, 
interventions. Therefore, policies probably involve adjust-
ments to DRG tariffs, or changes to clinical guidelines, and/
or hospital practice more generally. Hence, decision rules 
and policies for discontinuing the use of devices require 
attention in this context.
Notably, all participants reported to have no or little expe-
rience with refusing to confirm reimbursement at the end 
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of the schemes. While this may reflect the degree and type 
of uncertainties existing at the beginning of the schemes, it 
may also signal a certain difficulty in reversing the prelimi-
nary reimbursement decision once a technology has entered 
a scheme [17, 22, 23]. This aspect may be even more rel-
evant if no ex-ante criteria for evaluating the schemes were 
defined, as was the case for almost all schemes for devices 
in Europe.
Based on our observations of variation in the characteris-
tics of schemes, it is difficult to prescribe a single preferred 
approach to CED of devices in Europe. Each country has 
specific local differences in HTA practices, although knowl-
edge on how CED schemes have been used elsewhere can be 
used to develop local guidance. However, ideally a primary 
driver of the initiation of CED schemes would be the out-
come of HTAs for the technologies concerned, since this can 
help identify the uncertainties in (cost-) effectiveness that (in 
principle) could be resolved through CED.
The participants’ perceptions of the various challenges 
in initiating, designing, implementing, and evaluating CED 
schemes were varied and did not indicate that, in general, 
some challenges were substantially more important than oth-
ers. The reasons for this are unclear, although in some cases 
the participant’s perception of a given challenge reflected 
local circumstances. For example, funding was not perceived 
as a major challenge in settings where public funding was 
made available, but a major challenge in settings where it 
was not. In addition, the scores obtained for those challenges 
that were ‘device specific’ did not differ substantially from 
those for the other, more generic challenges. While this 
aspect requires further investigation, our general impression 
was that some of the low scores given for ‘device specific’ 
challenges are attributable to a lack of direct experience with 
addressing these issues, given that the use of CED schemes 
for medical devices in some European countries is generally 
quite recent. For example, it has been argued that manufac-
turers may be reluctant to engage in a scheme and generate 
new evidence if other competitors entering the market with 
fast-follower products could also benefit from it [24]. So, one 
option would be to require that each manufacturer generates 
the same clinical evidence as for devices already on the mar-
ket, unless there is compelling evidence of ‘equivalence’ for 
the new device [24, 25]. However, this option risks a waste 
of (public) resources in conducting clinical studies that are 
not strictly necessary. Moreover, the consequences of such 
a strategy in terms of competitiveness, market prices and 
eventually access of potentially valuable devices to patients 
remain largely unexplored.
We observed that the scores for the challenges were lower 
for respondents in countries where there was direct experi-
ence in CED for devices, as compared with those having 
experience with CED for drugs only. However, although 
the numerical differences in the scores were substantial, the 
small sample size means that no firm conclusions can be 
drawn. This could be explored in further research by com-
paring decision-makers’ perceptions before and after oper-
ating CED schemes and relating these perceptions to the 
general (HTA) infrastructure in a country.
We used a combination of methods to obtain insights in 
the use of and challenges related to CED schemes in the 
relatively understudied context of devices, including a large 
set of European countries. The insights obtained allow 
learning from experiences across countries and increase the 
chances of having successful CED schemes in the future, by 
highlighting how decision makers perceive and deal with 
specific challenges. Nonetheless, some limitations also need 
highlighting. First, although we studied experiences in many 
European countries, we cannot be sure that our overview is 
complete as some countries were not included in the study. 
Moreover, although in each country we interviewed the per-
son we considered to be most knowledgeable about CED 
schemes, we cannot be sure that the views of the participants 
are representative of the views of decision-makers more 
generally. Additionally, we focussed on the detailed percep-
tions of decision-makers, with a focus on HTA agencies at 
the national or regional level and (some) national payers 
because recent research suggests that decision-makers may 
be hesitant to engage in CED schemes [5]. This makes them 
not only a relevant source for the current study in terms of 
knowledge, but also in articulating (potential) challenges 
and difficulties with applying such schemes. Future studies 
could nonetheless supplement this with information on the 
perceptions of other stakeholders, such as clinical profes-
sionals, patient organisations, local payers/decision mak-
ers, and manufacturers. Finally, our focus was on schemes 
initiated at the national or regional level. In addition, some 
schemes involving devices may be negotiated at the local 
level directly between providers and manufacturers. Many of 
these may be ‘pay for performance’ schemes, but some could 
be characterized as CED schemes. These schemes were out-
side the scope of our current study, but their characteristics 
and performance are nonetheless important to investigate 
further.
Conclusions
CED schemes for medical devices offer a promising tool to 
increase value for money in health care. While they are cur-
rently used in Europe, this study has shown experience with 
these schemes to be limited to a relatively small number of 
countries. Moreover, considerable variation exists between 
countries in how schemes are initiated, designed, imple-
mented, and evaluated.
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While the identified challenges in using CED schemes 
were perceived differently, none of them was unanimously 
considered insignificant. Hence, all challenges should be 
considered when initiating CED schemes in a given coun-
try. Our recommendation is that each jurisdiction embarking 
on CED schemes for devices should undertake its own ‘risk 
assessment’, using our list of challenges as a starting point, 
and considering for each of them the factors that decision-
makers in this study outlined as having either a positive or 
negative influence. If a given challenge is considered to 
be important locally, the highlighted experiences of other 
countries in this study can help in addressing or overcoming 
them. That way, this study directly contributes to making 
CED schemes for devices a more effective policy option in 
the future.
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